Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2017 Apr;15(4):433-451.
doi: 10.6004/jnccn.2017.0044.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017

William J Gradishar  1 , Benjamin O Anderson  2 , Ron Balassanian  3 , Sarah L Blair  4 , Harold J Burstein  5 , Amy Cyr  6 , Anthony D Elias  7 , William B Farrar  8 , Andres Forero  9 , Sharon Hermes Giordano  10 , Matthew P Goetz  11 , Lori J Goldstein  12 , Steven J Isakoff  13 , Janice Lyons  14 , P Kelly Marcom  15 , Ingrid A Mayer  16 , Beryl McCormick  17 , Meena S Moran  18 , Ruth M O'Regan  19 , Sameer A Patel  12 , Lori J Pierce  20 , Elizabeth C Reed  21 , Kilian E Salerno  22 , Lee S Schwartzberg  23 , Amy Sitapati  4 , Karen Lisa Smith  24 , Mary Lou Smith  25 , Hatem Soliman  26 , George Somlo  27 , Melinda Telli  28 , John H Ward  29 , Dorothy A Shead  30 , Rashmi Kumar  30
Affiliations
Practice Guideline

NCCN Guidelines Insights: Breast Cancer, Version 1.2017

William J Gradishar et al. J Natl Compr Canc Netw. 2017 Apr.

Abstract

These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.

PubMed Disclaimer

Publication types

LinkOut - more resources